The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

NCT00556348

Age Related Macular Degeneration

COMPLETED PHASE4

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

NCT00423059

Diabetic Retinopathy

COMPLETED NA

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

NCT01256580

Choroidal Neovascularization Myopia Punctate Inner Choroidopathy (PIC) +5 more

WITHDRAWN NA

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

NCT00418431

Central Serous Chorioretinopathy

WITHDRAWN PHASE2/PHASE3

Bevacizumab Effect on Blood Velocity

NCT01298440

Choroidal Neovascularization

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Serous Chorioretinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravitreal injection with anterior paracentesis

0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bevacizumab (Avastin, Genetech) an antibody to vascular endothelial growth factor (VEGF)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of central serous chorioretinopathy
* Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
* Presence of focal leaks at the level of the RPE on fluorescein angiography